Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy


  • Multiple Sclerosis — Journal Insights Into: A Randomized Placebo-controlled Phase III Trial with a Novel Oral Drug for Multiple Sclerosis – Journal Insights
  • Laquinimod – a novel, oral, disease-modifying therapy – shows promise in reducing the progression of disability and brain atrophy in patients with relapsing-remitting MS. Join Fred D. Lublin, MD, and Timothy L. Vollmer, MD, as they discuss findings from the phase III BRAVO trial. Dr. Vollmer is the lead ... more >>
    F. Lublin, MD
  • Multiple Sclerosis — Expert Insight Into: 2-year RRMS Trial: Switching MS Patients from One First-line DMT to Another First-Line DMT (Part 1 of Series) – Article Review
  • Many patients taking first-line disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) experience suboptimal efficacy or intolerable side effects that may compromise treatment. Such patients may benefit from switching from one DMT to another. In this article review, Dr. Suhayl ... more >>
    S. Dhib-Jalbut, MD
  • Multiple Sclerosis — Multiple Sclerosis: The Advanced Curriculum VII – Certificate Program
  • Ongoing research in the field of multiple sclerosis (MS) has generated new insights into the pathophysiology, diagnosis, treatment, and management of this challenging disease. A wide array of new MRI technologies, new treatment strategies, and a better understanding of the need for early diagnosis and ... more >>
    F. Lublin, MD
    A. Miller, MD
  • Multiple Sclerosis: The Advanced Curriculum VII
  • Ongoing research in the field of multiple sclerosis (MS) has generated new insights into the pathophysiology, diagnosis, treatment, and management of this challenging disease. A wide array of new MRI technologies, new treatment strategies, and a better understanding of the need for early diagnosis and ... more >>
    F. Lublin, MD
    A. Miller, MD
  • Curriculum in Context: Multiple Myeloma

  • Curriculum In Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma. The curriculum includes six case studies at the point of care, a webcast, ...
    more >>
    N. Raje, MD
  • Curriculum In Context: Hepatitis C Virus

  • Curriculum In Context: Hepatitis C Virus (HCV) is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of HCV. The curriculum includes six case studies at the point of care and MedPage Today ...
    more >>
    P. Kwo, MD
    Z. Younossi, MD, MPH, FACG
  • Curriculum In Context: Inflammatory Bowel Disease

  • Curriculum In Context: Inflammatory Bowel Disease (IBD) is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of IBD. The curriculum includes six case studies at the point of care and ...
    more >>
    D. Rubin, MD
    L. Weinstock, MD, FACG
  • Multiple Sclerosis: The Advanced Curriculum VI
  • Ongoing research in the field of multiple sclerosis (MS) has generated new insights into the pathophysiology, diagnosis, treatment, and management of this challenging disease. A wide array of new MRI technologies, new treatment strategies, and a better understanding of the need for early diagnosis and ... more >>
    F. Lublin, MD
    A. Miller, MD
  • Curriculum In Context: Multiple Myeloma

  • Curriculum In Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma. The curriculum includes six case studies at the point of care and MedPage ...
    more >>
    K. Anderson, MD
  • Idiopathic Pulmonary Fibrosis: Case Studies
  • Idiopathic Pulmonary Fibrosis—Case Studies is a series of compelling CME/CE-accredited case studies that deliver the latest scientific data about the management of idiopathic pulmonary fibrosis, framed around real-world patient scenarios commonly seen in daily practice. The case simulations add a level of ... more >>
    M. Padilla, MD
  • A Curriculum for the Management of T2DM Patients with SGLT-2 Inhibitors
  • The unprecedented increase in recently improved and emerging antidiabetic agents seen over the last few years has dramatically expanded the ability of clinicians to treat patients with type 2 diabetes. Among the newest of these agents are the sodium glucose cotransporter 2 (SGLT-2) inhibitors, a class of ... more >>
    V. Fonseca, MD, FRCP
  • Case-Based Practice Improvement Video Vignette Collection: Rheumatoid Arthritis Edition
  • Through a collection of six patient video case vignettes, this point-of-care clinical companion provides rheumatologists and other clinicians with valuable instruction on the use of disease-modifying antirheumatic drugs (DMARDs), and current and emerging biologic agents as initial treatment for patients with ... more >>
    D. Furst, MD, MSPH
  • T2DM Tool Kit: Managing Patients with Incretin-Based Therapies
  • A Tool Kit for the Management of T2DM Patients with Incretin-Based Therapies is an online CME/CE program, chaired by Anne Peters, MD, that employs multiple educational formats to provide clinicians with tools and training to enhance the care of patients with type 2 diabetes mellitus (T2DM). Through a webcast, ... more >>
    A. Peters, MD
  • MedImage Cases-Neurology: Multiple Sclerosis
  • The MS MedImage Cases® library discusses the MRI as a tool to guide practical therapeutic approaches and measure disease activity, progression, and response to therapy. New collaboration tools: Share Your Knowledge® comment on a particular aspect of a presented case. Share Your Case® €”submit a challenging ... more >>
    D. Pelletier, MD
  • Rheumatoid Arthritis @Point of Care
  • Early diagnosis, prompt intervention, and maintenance of tight disease control are now known to be key in preventing or slowing progression of rheumatoid arthritis (RA). Many patients do not achieve or sustain remission with older disease-modifying agents alone. Biologic therapies for RA have helped many ... more >>
    P. Mease, MD
  • Update - Making Sense of New and Emerging Treatment Options for COPD
  • Chronic obstructive pulmonary disease (COPD) is highly prevalent in the United States. About 13 million people have a diagnosis of COPD, yet the disease remains underdiagnosed, with an estimated 21 million individuals affected. Cigarette smoking is the primary cause and, while smoking rates have dropped, they ... more >>
    B. Make, MD
  • Myelodysplastic Syndromes and Acute Myeloid Leukemia @Point of Care
  • The Myelodysplastic Syndromes and Acute Myeloid Leukemia @Point of Care is always updated and always current. Point of care accessibility allows clinicians to answer practice-based questions by accessing a robust and easily searchable knowledge base, this interactive point-of-care resource tool offers expert- ... more >>
    J. Radich, MD, MS
  • Parkinson's Disease @Point of Care
  • From 2005 to 2030, the number of patients with Parkinson’s disease is expected to double. Caroline M. Tanner, MD, PhD provides an overview of the epidemiology of Parkinson’s disease and its associated morbidity in this subchapter of the Parkinson’s Disease @POC program.
    R. Hauser, MD, MBA
  • Advances in Immuno-Oncology
  • Immuno-Oncology @Point of Care, featuring Jeffrey S. Weber, MD, PhD as Editor-in-Chief, is a clinical support platform that provides comprehensive information on immuno-oncology and the role of immune-based medicines in treating cancer, made up of a progressive series of chapters and other learning tools. It ... more >>
    J. Weber, MD, PhD
  • Non-Small Cell Lung Cancer @Point of Care
  • Advances in our understanding of non-small-cell lung cancer (NSCLC) are leading to new strategies for diagnosis, staging, and treatment. This point-of-care clinical resource can help you stay informed about disease pathogenesis, molecular targets, and current and emerging management strategies based on the ... more >>
    M. Socinski, MD
  • Hypoparathyroidism @Point of Care
  • Rare disorders, such as hypoparathyroidism, present a challenge for clinicians to keep abreast of new developments and changes in best practices. The Hypoparathyroidism @Point of Care Edition provides a comprehensive examination of the latest evidence-based data for optimizing current patient identification, ... more >>
    J. Bilezikian, MD
  • Gynecologic Cancers @Point of Care
  • This interactive CME/CE textbook provides comprehensive coverage of important ovarian cancer and cervical cancer-related topics, supplemented by hyperlinks to external multimedia resources such as illustrations, videos, journal articles, and other resources, that enhance understanding of relevant issues.
    B. Monk, MD, FACS, FACOG
  • Multiple Sclerosis @Point of Care
  • MS @Point of Care is a clinical decision support platform that provides comprehensive information on the diagnosis, treatment and management of multiple sclerosis, made up of a progressive series of chapters and other learning tools. It provides multimedia offerings, and contextual expansion of content ... more >>
    B. Cohen, MD
    P. Coyle, MD
  • Primary Biliary Cirrhosis — PBC and NASH: Progress on the Horizon – Webcast
  • Chronic liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), are leading causes of morbidity and mortality in the United States. PBC and NASH differ with respect to their epidemiology, presentation, management options, and response to treatment. The burden of these ... more >>
    A. Sanyal, MD
  • Primary Biliary Cirrhosis — PBC and NASH: Progress on the Horizon – Satellite Symposium
  • This live symposium has ended

    A webcast of the live presentations will be available soon.
    If you would like to be notified once it is available, please email us at pbcBoston@projectsinknowledge.com [Include "PBC/NASH Webcast—Inform Me" in the subject heading].

    Presented for attendees of the 65th AASLD ...
    more >>
    A. Sanyal, MD
  • Multiple Myeloma — Focus on the Role of Proteasome Inhibitors in the Management of Multiple Myeloma – Webcast
  • Clinicians need to know how to incorporate proteasome inhibitors into treatment plans for patients with multiple myeloma, whether they are newly diagnosed or are experiencing relapsed/refractory disease. Join our co-faculty Sagar Lonial, MD, and Kenneth C. Anderson, MD, for this webcast, Focus on the Role of ... more >>
    S. Lonial, MD
  • Pulmonology — Making Sense of New and Emerging Treatment Options for COPD – Webcast
  • Recent advances have led to important changes in the paradigm for the treatment of COPD. Join Dr. Barry Make and Dr. James Donohue as they discuss the current emphasis on personalized treatment based on expanded factors in patient assessment, together with the development of new and emerging treatment options ... more >>
    B. Make, MD
  • Hepatitis C — Hepatitis C Treatment Goes Viral: Let's Talk About Oral Therapies – Webcast
  • This compelling webcast features expert-guided presentations on the current state of oral therapies for chronic hepatitis C virus (HCV) infection. Learn the implications of clinical trial results, and how the latest advances are affecting today's real-world clinical practice.
    I. Jacobson, MD
  • Primary Biliary Cirrhosis — Changing Dynamics in the Science and Clinical Management of Primary Biliary Cirrhosis: What they Mean for Us, What They Mean for Our Patients – Webcast
  • There are several types of chronic liver disease, including primary biliary cirrhosis (PBC), and there remain several challenges in the management of this disease. Join Dr. David Jones, Program Chair, and Dr. Ulrich Beuers, Distinguished Faculty, as they offer insight into recent developments in the ... more >>
    D. Jones, MD, PhD
  • Multiple Sclerosis — Improving the Management of Walking Impairment and Foot Drop in MS – Webcast
  • Almost two-thirds of MS patients report significant difficulty in walking. Yet, approximately 40% of patients with MS rarely or never discuss this problem with their physicians. As a result of this gap in communication, many MS patients do not experience the benefits of available pharmacologic and ... more >>
    A. Goodman, MD
  • Primary Biliary Cirrhosis — Novel Therapeutic Targets in PBC, PSC, and NASH: Translating Knowledge into Tomorrow's Practice – Webcast
  • There are several types of chronic liver disease, including primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), and each disease state differs with respect to its epidemiology, presentation, management options, and response to treatment. Management ... more >>
    H. Bodenheimer Jr, MD
  • Tumor Immunology — Highlights from ASCO 2013: Novel Therapies for Advanced Melanoma – Podcast Series
  • With more effective therapies for advanced melanoma badly needed, the advent of anti-CTLA-4 and anti-PD-1 antibodies, along with other emerging agents, has been an exciting development. Join four experts in the field as they present highlights from ASCO 2013 in this breaking area.
    J. Weber, MD, PhD
  • Multiple Sclerosis — How Can We Better Manage MS Patients Today? – Webcast
  • As in the case of other chronic diseases for which treatment slows disease progression but does not provide a cure, maintaining treatment adherence over the long term is a challenge for patients with MS and their physicians. Determining treatment with both clinical outcomes and adherence in mind is ... more >>
    D. Goodin, MD
  • Hepatitis C — HCV Case Study: HCV Therapy for a Treatment-Experienced Noncirrhotic Patient with HCV Genotype-1a Infection and the Q80K Polymorphism – Case Study
  • Emerging interferon-free therapies will offer a variety of treatment options for patients with hepatitis C genotype-1 infection. The challenge for the clinician will be to evaluate patient-specific factors in order to select the regimen most likely to achieve sustained virologic response. Join Mark S. ... more >>
    M. Sulkowski, MD
  • Hepatitis C — HCV Case Study: HCV Therapy for a Genotype-1b Patient Intolerant to IFN-Based Therapies – Case Study
  • Emerging interferon-free regimens will offer treatment options to patients who have had prior nonresponse or intolerable adverse effects with peginterferon/ribavirin. Phase III testing of these regimens have evaluated efficacy in various patient subgroups, including HCV genotype subtypes, in order to ... more >>
    M. Sulkowski, MD
  • Multiple Sclerosis — Differentiating Multiple Sclerosis and Neuromyelitis Optica Based on MRI Findings – MedImage Case
  • Neuromyelitis optica and multiple sclerosis are difficult to differentiate based on clinical presentation alone. Join Dr. Augusto A. Miravalle for a case-based discussion of how to use MRI make the distinction between these two neurologic disorders.
    A. Miravalle, MD
  • Multiple Sclerosis — Sequencing Disease-Modifying Therapies in Relapsing Remitting MS – MedImage Case
  • Patients with relapsing-remitting multiple sclerosis often need to switch therapies due to breakthrough disease or tolerability issues. No guidelines exist, however, to guide clinicians through the switching process. In this case-based podcast, Dr. Flavia M. Nelson models how to select a patient’s next ... more >>
    F. Nelson, MD
  • Multiple Sclerosis — Switching Disease-Modifying Therapy in Relapsing Remitting MS Due to Disease Disability – MedImage Case
  • Join Patricia K. Coyle MD, for this podcast about how to use MRI to evaluate patients who progress while on multiple sclerosis disease-modifying therapy. In this case-based discussion, Dr. Coyle will review when to order spinal cord MRI, how to optimize imaging protocols, and how to use MRI findings to inform ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — Role of MRIs in Assessing New Treatments for SPMS and PPMS – MedImage Case
  • In this podcast, Christina J. Azevedo, MD, discusses completed and ongoing drug trials for the treatment of primary-progressive and secondary-progressive multiple sclerosis, with a specific emphasis on MRI outcomes.
    C. Azevedo, MD
  • Inflammatory Bowel Disease — IBD Case Study: Management of Moderate Ulcerative Colitis That Rapidly Progresses Following Initial 5-ASA Therapy – Case Study
  • First-line treatment with aminosalicylates (5-ASA) is commonly used for patients diagnosed with mild-moderate ulcerative colitis and is often successful. For patients who progress on initial 5-ASA therapy, it may be necessary to use alternative treatments, such as anti-tumor necrosis factor therapy. In this ... more >>
    D. Binion, MD
  • Inflammatory Bowel Disease — IBD Case Study: Diagnosis and Treatment of Moderate Ulcerative Colitis – Case Study
  • For patients diagnosed with mild-moderate ulcerative colitis, treatment with aminosalicylates (5-ASA) is the standard of care. However, there are a number of different options available for 5-ASA therapy. In this case study, Stephen B. Hanauer, MD, discusses the treatment of a patient diagnosed with moderate ... more >>
    S. Hanauer, MD
  • Multiple Sclerosis — Early Diagnosis and Treatment of Relapsing Remitting Multiple Sclerosis – MedImage Case
  • What is the role of MRI in diagnosing MS? What is the role of MRI in making treatment decisions? Join Robert Bermel, MD, for this podcast in which he models using MRI to stratify patients according to risk of progression, to inform treatment selection, and to evaluate treatment response by evaluating lesions ... more >>
    R. Bermel, MD
  • Multiple Sclerosis — Improving Adherence in Relapsing-Remitting Multiple Sclerosis – MedImage Case
  • Join James D. Bowen, MD, for this podcast about the range of therapeutic options for patients with relapsing-remitting MS who are having difficulty adhering to their current disease-modifying therapy as prescribed.
    J. Bowen, MD